2021 Exhibitor List X Showroom

BIORCHESTRA’s BMD-001 targets a microRNA thought to be the cause of Alzheimer’s disease by intravenously administering a microRNA inhibiting antisense oligonucleotide to individuals that display an overexpression microRNA profile and has been specifically developed to allow enhanced delivery into brain cells. Furthermore, it has been designed such that following IV administration of BMD-001, the quantification of plasma or saliva microRNA concentrations can be used to predict the therapeutic efficacy of the drug. We developed a brain target drug delivery system to safely deliver ASO to brain cells through intravenous injection. The transmittance efficiency is about 7% (Rodent).